Vuzix Receives New Orders for Over $1.2 million of Smart Glasses from Rods & Cones to Support Virtual Surgical Collaboration Rollout

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that the Company has received new orders from Rods & Cones, a provider of a fully virtual surgical-collaboration platform, for monthly deliveries of Vuzix M400 Smart Glasses beginning immediately and over the remainder of 2021.

The orders, valued in excess of €1 million or more than $1.2 million at current exchange rates, will support optimized remote interactions between surgeons and experts in the operating theatre using Vuzix M400 Smart Glasses.

The Rods & Cones platform, combined with the Vuzix M400 Smart Glasses’ 13 MP phase-detect autofocus camera, will let frontline workers in the operating room, ICU, or other medical facility, including surgeons, instrumentalist nurses, and other healthcare professionals, provide 4K broadcast-quality imagery to others while interacting with patients and staff from a safe distance. This combined solution will also allow remote platform users to attend significantly more supported surgeries in a single day.

“We are excited to have placed these new orders with Vuzix for their powerful Smart Glasses to support our growing needs as a surgical and healthcare service provider across Europe and the United States,” said Bruno Dheedene, CEO and co-founder of Rods & Cones.

“Vuzix Smart Glasses are ideally suited to be an integral part of the Rods & Cones surgical-collaboration platform and we are pleased to help support their current, as well as future deployments across their network of healthcare professionals to deliver surgical and medical services,” said Paul Travers, President and CEO of Vuzix.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version